{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:54:27Z","timestamp":1793040867631,"version":"4.5.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In relapsed\/refractory Hodgkin lymphoma (R\/R HL), immunotherapies such as the anti-programmed death-1 inhibitor pembrolizumab have demonstrated efficacy as monotherapy and are playing an increasingly prominent role in treatment. The CD30\/CD16A-bispecific antibody AFM13 is an innate immune cell engager, a first-in-class, tetravalent antibody, designed to create a bridge between CD30 on HL cells and the CD16A receptor on natural killer cells and macrophages, to induce tumor cell killing. Early studies of AFM13 have demonstrated signs of efficacy as monotherapy for patients with R\/R HL and the combination of AFM13 with pembrolizumab represents a rational new treatment modality. Here, we describe a phase 1b, dose-escalation study to assess the safety and preliminary efficacy of AFM13 in combination with pembrolizumab in patients with R\/R HL. The primary objective was estimating the maximum tolerated dose; the secondary objectives were to assess safety, tolerability, antitumor efficacy, pharmacokinetics, and pharmacodynamics. In this heavily pretreated patient population, treatment with the combination of AFM13 and pembrolizumab was generally well tolerated, with similar safety profiles compared to the known profiles of each agent alone. The combination of AFM13 with pembrolizumab demonstrated an objective response rate of 88% at the highest treatment dose, with an 83% overall response rate for the overall population. Pharmacokinetic assessment of AFM13 in the combination setting revealed a half-life of up to 20.6 hours. This proof-of-concept study holds promise as a novel immunotherapy combination worthy of further investigation. This phase 1b study was registered at www.clinicaltrials.gov as NCT02665650.<\/jats:p>","DOI":"10.1182\/blood.2019004701","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T21:26:25Z","timestamp":1596144385000},"page":"2401-2409","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":141,"title":["A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma"],"prefix":"10.1182","volume":"136","author":[{"given":"Nancy L.","family":"Bartlett","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-090X","authenticated-orcid":false,"given":"Eva","family":"Domingo-Domenech","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0537-4207","authenticated-orcid":false,"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Forero-Torres","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-2787","authenticated-orcid":false,"given":"Ramon","family":"Garcia-Sanz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumana","family":"Devata","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia Rodriguez","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"Hematological Malignancies Site Disease Group, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Reeder","sequence":"additional","affiliation":[{"name":"Hematology Department, Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Sher","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic, Jacksonville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia E.","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Affimed GmbH, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Alland","sequence":"additional","affiliation":[{"name":"Affimed, Inc., New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Strassz","sequence":"additional","affiliation":[{"name":"Affimed GmbH, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Prier","sequence":"additional","affiliation":[{"name":"Affimed GmbH, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Choe-Juliak","sequence":"additional","affiliation":[{"name":"Affimed, Inc., New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2020120315405082400_B1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nrclinonc.2012.91","article-title":"State of the art in the treatment of Hodgkin lymphoma","volume":"9","author":"Borchmann","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"2020120315405082400_B2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"34","key":"2020120315405082400_B3","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","article-title":"Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma","volume":"28","author":"Josting","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020120315405082400_B4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","article-title":"Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma","volume":"146","author":"Moskowitz","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"2020120315405082400_B5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","article-title":"Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant","volume":"54","author":"Arai","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2020120315405082400_B6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ajh.24792","article-title":"Outcomes of patients with relapsed\/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis","volume":"92","author":"Bair","year":"2017","journal-title":"Am J Hematol"},{"issue":"39","key":"2020120315405082400_B7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/EDBK_238799","article-title":"Relapsed and refractory classical Hodgkin lymphoma: keeping pace with novel agents and new options for salvage therapy","volume":"39","author":"Moskowitz","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"18","key":"2020120315405082400_B8","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"2020120315405082400_B9","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"2020120315405082400_B10","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin Lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020120315405082400_B11","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin Lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2020120315405082400_B12","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2018-99-118506","article-title":"A phase 1b study investigating the combination of the tetravalent bispecific NK cell engager AFM13 and pembrolizumab in patients with relapsed\/refractory Hodgkin Lymphoma after brentuximab vedotin failure: updated safety and efficacy data","volume":"132","author":"Bartlett","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2020120315405082400_B13","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/19420862.2019.1616506","article-title":"Redirected optimized cell killing (ROCK\u00ae): a highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity","volume":"11","author":"Ellwanger","year":"2019","journal-title":"MAbs"},{"issue":"3","key":"2020120315405082400_B14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells","volume":"6","author":"Reusch","year":"2014","journal-title":"MAbs"},{"issue":"5","key":"2020120315405082400_B15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000479981","article-title":"Recombinant antibodies to arm cytotoxic lymphocytes in cancer immunotherapy","volume":"44","author":"Koch","year":"2017","journal-title":"Transfus Med Hemother"},{"issue":"5","key":"2020120315405082400_B16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/2326-6066.CIR-17-0550","article-title":"CD16A activation of NK cells promotes NK cell proliferation and memory-like cytotoxicity against cancer cells","volume":"6","author":"Pahl","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"suppl 1","key":"2020120315405082400_B17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1182\/blood-2018-99-118427","article-title":"CD16A-Specific Tetravalent Bispecific Immune Cell Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) on Macrophages","volume":"132","author":"Wingert","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2020120315405082400_B18","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2020120315405082400_B19","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"27","key":"2020120315405082400_B20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020120315405082400_B21","doi-asserted-by":"crossref","first-page":"E1071","DOI":"10.3390\/cancers11081071","article-title":"Immunotherapy in Hodgkin Lymphoma: present status and future strategies","volume":"11","author":"Vassilakopoulos","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2020120315405082400_B22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"issue":"2","key":"2020120315405082400_B23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"2020120315405082400_B24","doi-asserted-by":"crossref","first-page":"9513701","DOI":"10.1155\/2019\/9513701","article-title":"Immune checkpoint inhibition in classical Hodgkin Lymphoma: from early achievements towards new perspectives","volume":"2019","author":"De Goycoechea","year":"2019","journal-title":"J Oncol"},{"issue":"14","key":"2020120315405082400_B25","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2020120315405082400_B26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","article-title":"NK cell recognition","volume":"23","author":"Lanier","year":"2005","journal-title":"Annu Rev Immunol"},{"issue":"16","key":"2020120315405082400_B27","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/21\/2401\/1789957\/bloodbld2019004701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/21\/2401\/1789957\/bloodbld2019004701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T15:44:59Z","timestamp":1607010299000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/21\/2401\/461621\/A-phase-1b-study-of-AFM13-in-combination-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":27,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020,11,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019004701","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]}}}